RESUMO
Objective To analyze the epidemiological characteristics of the novel coronavirus pneumonia epidemic in Hebei Province, and to provide a scientific basis for the prevention and control of the novel coronavirus pneumonia epidemic. Methods Descriptive epidemiological methods were used to analyze the epidemiological characteristics of all COVID-19 cases reported in Hebei Province from January 22, 2020 to September 22, 2020. Results As of September 22, 2020, a total of 365 confirmed cases had been reported in Hubei Province, including 339 local confirmed cases and 26 imported cases, of which 18 were critical cases, 34 severe cases, and 6 deaths. Among the confirmed cases, 198 were males and 167 were females, with a male to female ratio of 1.19:1. The epidemic situation in Hebei Province can be divided into three stages: The first stage (January 22 to April 6) was dominated by imported cases from Hubei Province, with 318 reported cases, accounting for 87.12% of the total cases, and the mortality rate was 1.89%; The second stage (June 14 - July 25) was the spread caused by cases in Beijing Xinfadi market, with 21 cases reported, accounting for 5.75% of the total cases, and the mortality rate was 0%; The third stage (July 26 - September 22) was mainly imported cases from abroad, with 26 cases reported, accounting for 7.12% of the total cases, and the mortality rate was 0%. Conclusion The COVID-19 epidemic situation in Hebei Province has been under control. In view of the continuous spread of the epidemic situation in foreign countries, it is extremely important to strictly prevent the import of overseas epidemics and prevent the outbreak from rebounding.
RESUMO
Objective@#To evaluate the changes of molecular markers of thrombosis in patients with deep venous thrombosis of lower extremities and analyze their value in the detection of venous thrombosis and evaluate the therapeutic effects. @*Methods@#In case-control study, we selected traumatic patients after surgery from Beijing Jishuitan Hospital during December 2018 to May 2019. A total of 64 patients with thrombosis were in DVT group, 39 patients without thrombosis were in non-DVT group, and 28 healthy subjects in the same period were in healthy control group. Venous blood samples were taken from all these people. Coagulation parameters thrombin-antithrombin complexes (TAT), plasmin-α2-plasmin inhibitor complexes (PIC) and tissue-type plasminogen activator-inhibitor complexes (t-PAIC) were detected at first diagnosis and one month after rivaroxaban anticoagulation therapy beginning. The differences of the markers between these groups were compared. @*Results@#The coagulation markers of the patients with lower extremity deep venous thrombosis increased significantly at diagnosis. The levels of plasma TAT, PIC, t-PAIC and sTM in DVT group were significantly higher than those in non-DVT group (P＜0.05). The levels of plasma TAT, PIC and t-PAIC in DVT group were higher than those in healthy control group (P＜0.05). There was no significant difference in sTM level between DVT group and healthy control group (P＞0.05). The results and changes of TAT, PIC, t-PAIC in the patients before and after one month of anticoagulation therapy were statistically different (P＜0.05) in comparison. @*Conclusion@#The molecular markers of thrombosis, TAT, PIC and t-PAIC, could effectively detect deep venous thrombosis of lower extremities and showed significant efficacy in evaluating the efficacy of anticoagulation therapy.
RESUMO
Thrombotic microangiopathy (TMA) is a group of acute clinical pathological syndromes with common pathological features, which include hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic purpura syndrome. They have many similarities in etiology and clinical presentation. The role of abnormal activation of complement bypass pathway in the genesis and development of HUS has been recognized. More than 100 kinds of complement regulatory factors or gene mutations of complement itself were found to be associated with the development of HUS, which resulted in the decrease of negative complement regulatory protein activity or the increase of complement activation protein function . Abnormal activation of complement system resulted in endothelial injury and thrombosis. Loss of ADAMTS13 activity (<10％) is the most important pathogenesis of TTP. However, there are more and more evidence that complement bypassing pathway is over-regulated and over-activated in the formation of TTP. At present, the research of TMA is focused on finding specific complement-activated biomarkers in patients with various forms of TMA and developing new targeted therapeutic drugs for the disease.
RESUMO
Thrombotic microangiopathy (TMA) is a group of acute clinical pathological syndromes with common pathological features, which include hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic purpura syndrome. They have many similarities in etiology and clinical presentation. The role of abnormal activation of complement bypass pathway in the genesis and development of HUS has been recognized. More than 100 kinds of complement regulatory factors or gene mutations of complement itself were found to be associated with the development of HUS, which resulted in the decrease of negative complement regulatory protein activity or the increase of complement activation protein function. Abnormal activation of complement system resulted in endothelial injury and thrombosis. Loss of ADAMTS13 activity (<10%) is the most important pathogenesis of TTP. However, there are more and more evidence that complement bypassing pathway is over-regulated and over-activated in the formation of TTP. At present, the research of TMA is focused on finding specific complement-activated biomarkers in patients with various forms of TMA and developing new targeted therapeutic drugs for the disease.